|
Volumn 30, Issue 1, 1996, Pages 257-267
|
Developing a regulatory strategy for monoclonal antibodies
a b,c b |
Author keywords
Biologics; Drug development; Monoclonal antibodies; Regulatory issues; Regulatory strategy
|
Indexed keywords
ABCIXIMAB;
BICIROMAB;
CENTOXIN;
EDRECOLOMAB;
IMCIROMAB;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY B.72.3;
MONOCLONAL ANTIBODY E5;
OKT 3;
ONCOSCINT CR OV;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG LABELING;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG RESEARCH;
DRUG SAFETY;
DRUG SCREENING;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MULTICENTER STUDY;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
REVIEW;
UNITED STATES;
|
EID: 0030066328
PISSN: 00928615
EISSN: None
Source Type: Journal
DOI: 10.1177/009286159603000129 Document Type: Review |
Times cited : (5)
|
References (4)
|